ALNY
Alnylam Pharmaceuticals, Inc.
NMS
$286.12
-9.51
(-3.22%)
Pullback · -1.16σ
132-Day TAO Zones
21 EMA
+1 ATR
+2 ATR
−2 ATR
—
O —
H —
L —
C —
—
—
Key statistics
Mkt cap
$38.2B
P/E ttm
71.7
Fwd P/E
20.6
Beta
0.30
Day range
$286.12
52w range
$284.28 – $479.79
Avg vol
1.1M
RSI(2)
8.3
ROE
90.4%
Net mgn
12.6%
FCF mgn
4.8%
Debt/Eq
2.76
Div yld
—
Sector
Healthcare
Industry
Biotechnology
Next earn
2026-07-30
Matrix setup grades
Long
—
score 17 · tech 17 / 80 · support 0 / 20
KC1 lower, -1.09 ATR from EMA21 · no notable pattern
- · KC1 lower stretch — light dip
Short
—
score 15 · tech 15 / 80 · support 0 / 20
below KC1 upper, -1.09 ATR from EMA21 · no notable pattern
- · Stochastic bear cross
- · Aligned with weak downtrend
Options · swing
See more →
CALL
$300
2026-07-17
$12.05
PUT
$300
2026-07-17
$23.85
Insider activity
See more →No Form 4 filings in the last 30 days.
Earnings
See more →- Last reported
- 2026-04-30
- EPS (act / est)
- 1.99 / 1.47
- Surprise
- +35.3%
- Next report
- 2026-07-30
About
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; G…